首页> 美国卫生研究院文献>Molecules >Development of a UPLC-MS/MS Method for Simultaneous Determination of Six Flavonoids in Rat Plasma after Administration of Maydis stigma Extract and Its Application to a Comparative Pharmacokinetic Study in Normal and Diabetic Rats
【2h】

Development of a UPLC-MS/MS Method for Simultaneous Determination of Six Flavonoids in Rat Plasma after Administration of Maydis stigma Extract and Its Application to a Comparative Pharmacokinetic Study in Normal and Diabetic Rats

机译:建立UPLC-MS / MS方法同时测定柱头Maydis柱提取物后大鼠血浆中六种类黄酮的含量及其在正常和糖尿病大鼠中的药代动力学比较研究中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Maydis stigma is an important medicine herb used in many parts of the world for treatment of diabetes mellitus, which main bioactive ingredients are flavonoids. This paper describes for the first time a study on the comparative pharmacokinetics of six active flavonoid ingredients of Maydis stigma in normal and diabetic rats orally administrated with the decoction. Therefore, an efficient and sensitive ultra high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous determination of six anti-diabetic ingredients (cynaroside, quercetin, luteolin, isorhamnetin, rutin and formononetin) of Maydis stigma in rat plasma has been developed and validated in plasma samples, which showed good linearity over a wide concentration range (r2 > 0.99), and gave a lower limit of quantification of 1.0 ng·mL−1 for the analytes. The intra- and interday assay variability was less than 15% for all analytes. The mean extraction recoveries and matrix effect of analytes and IS from rats plasma were all more than 85.0%. The stability results showed the measured concentration for six analytes at three QC levels deviated within 15.0%. The results indicated that significant differences in the pharmacokinetic parameters of the analytes were observed between the two groups of animals, whereby the absorptions of these analytes in the diabetic group were all significantly higher than those in the normal group, which provides an experimental basis for the role of Maydis stigma in anti-diabetic treatment.
机译:Maydis stigma是世界上许多地方用于治疗糖尿病的重要草药,其主要生物活性成分是类黄酮。本文首次描述了在口服普通和糖尿病大鼠中,Maydis柱头的六种活性黄酮类成分的比较药代动力学的研究。因此,一种高效灵敏的超高效液相色谱-串联质谱(UPLC-MS / MS)方法可同时测定Maydis柱头的六种抗糖尿病成分(人参皂苷,槲皮素,木犀草素,异鼠李素,芦丁和甲萘醌)在大鼠血浆中的血浆样品已经开发并验证,在宽浓度范围内(r 2 -1 用于分析物。所有分析物的日内和日间分析变异性均小于15%。从大鼠血浆中分析物和IS的平均提取回收率和基质效应均超过85.0%。稳定性结果表明,在三个QC水平下,六种分析物的测量浓度相差15.0%。结果表明,在两组动物之间观察到分析物的药代动力学参数存在显着差异,从而糖尿病组中这些分析物的吸收均显着高于正常组中的吸收,这为动物实验提供了实验依据。 Maydis柱头在抗糖尿病治疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号